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Oocyte cryopreservation — relevance for all 
medical practitioners in South Africa
To the Editor: This literature review was undertaken 
to investigate the efficacy of the two different freezing 
methods currently used in oocyte cryopreservation.
Published literature in which the outcomes of fresh and 
frozen cycles – both slow- and fast-freeze (vitrification) 
methods – in assisted reproductive techniques (ART) were 
reported during the period 1999 - 2009 was reviewed. 
Metalib was used to search across multiple databases for 
the period 1999 - 2009, to identify studies that answered 
the question ‘What are the fertilisation, implantation 
and pregnancy rates achieved when using fresh or 
frozen oocytes?’ The scientific background, current 
developments and results of these three methods were 
reviewed. In addition, references of the retrieved articles 
were hand-searched.
Oocyte cryopreservation has proved to be a useful 
technique, as it gives women who are about to undergo 
chemotherapy, radiotherapy or oophorectomy a chance 
to preserve their fertility. Healthy women can also make 
use of this technology to preserve their fertility and delay 
childbearing age. Other non-oncological conditions for 
desiring fertility preservation may be auto-immune or 
haematological diseases requiring chemotherapy, and 
excision of an ovarian cyst, possibly resulting in damage 
to the ovarian cortex and premature ovarian failure.1 As 
a result of this technology, couples who make use of ART 
may now freeze their oocytes rather than their embryos. 
Once their family has been completed, it is emotionally 
much easier to dispose of frozen oocytes rather than 
embryos.
Cryopreservation of oocytes allows patients to avoid 
a few of the many ethical, moral and religious issues 
connected with embryo cryopreservation. However, in 
contrast to the embryo, the oocyte is more sensitive to 
the cryopreservation process owing to its high water 
content, which predisposes it to damage caused by ice 
crystal formation.
Currently there are two methods for cryopreservation: 
slow freeze, rapid thaw and fast freeze or vitrification. 
The slow-freeze method is a time-consuming process, 
taking up to 3 hours, and requires expensive computerised 
equipment. Vitrification, or fast freeze, is a far more time-
efficient method that does not require costly equipment 
and is therefore far more economical.
The results of this review compared the outcomes of slow 
freezing and vitrification methods with those achieved in 
fresh cycles in ART. Fresh cycles showed fertilisation rates 
after intra-cytoplasmic sperm injection (ICSI) of between 
73.4% and 96.6%, and cleavage rates between 71.5% and 
97.9%. Implantation rates per embryo transferred were 
5.5 - 39.8% and pregnancy rates per embryo transfer 
cycle 10.3 - 48.9%. Slow-freeze cycles showed survival 
rates after thawing of 37.0 - 95.8%, fertilisation rates 
after ICSI of 45.4 - 89.7%, cleavage rates of 76.5 - 100%, 
implantation rates per embryo transferred of 2.2 - 62.5%, 
and pregnancy rate per embryo transfer cycle of 4.2 - 
37.5%. Vitrification cycles showed survival rates after 
thawing of 68.6 - 99.4%, fertilisation rates after ICSI of 
70.6 - 93.0%, cleavage rates of 89.8 - 100%, implantation 
rates per embr yo transferred of 6.4 - 45.3%, and 
pregnancy rates per embryo transfer cycle of 17.6 - 80.0% 
(Table I).
All three ART methods reviewed here (fresh cycle, slow 
freeze and vitrification) have varying success rates, which 
have all shown improvement over the years. Ultimately 
it seems that with further innovation, vitrification will 
become the leading method of oocyte cryopreservation 
simply owing to its time efficiency, the simplicity and 
safety of the method, and the reduction in costs by 
eliminating the need for costly machinery. Although initial 
survival, fertilisation and cleavage rates for cryopreserved 
oocytes were relatively poor, the advancements made 
in cryoprotectants and method protocols in the recent 
past have caused these rates to improve steadily. Oocyte 
cryopreservation can therefore be offered as a standard 
Table I. Comparison of the outcomes of all three methods
Summary
Fresh
(9 articles)
Slow freeze
(16 articles)
Vitrification
(9 articles)
Survival rate  37.0 - 95.8% 68.6 - 99.4%
Fertilisation rate 73.4 - 96.6% 45.4 - 89.7% 70.6 - 93.0%
Cleavage rate 71.5 - 97.9% 76.5 - 100% 89.8 - 100%
Implantation rate/ET 5.5 - 39.8% 2.2 - 62.5% 6.4 - 45.3%
Pregnancy rate/ETC 10.3 - 48.9% 4.2 - 37.5%
17.7 - 80.0% 
(average 42.8%)
ET = embryo transfer; ETC = embryo transfer cycle.
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of care, not only to patients wishing to delay fertility 
because of imminent cancer therapy but also to couples 
who refuse embryo cryopreservation or in countries 
where there are limits on fresh oocyte fertilisation and 
where embryo freezing is prohibited.
It is important for medical practitioners to take note of 
the indications for oocyte cryopreservation, which may 
be both oncological and non-oncological. They are as 
follows:
Oncological conditions2
•  Cancers. Patients may require ionising radiation or an 
alkylating agent, which may be gonadotoxic, causing 
premature ovarian failure and infertility.
•  Cytotoxic agents. Bone marrow transplants may be 
used for the treatment of haematological disorders 
such as sickle cell anaemia, as well as cancerous 
haematological disease. High-dose chemotherapy is 
used to destroy existing bone marrow. Auto-immune 
diseases such as systemic lupus erythematosus, multiple 
sclerosis and rheumatoid arthritis often affect women 
of reproductive age, and these diseases are also treated 
with cytotoxic drugs such as cyclophosphamide or 
methotrexate.
Non-oncological conditions1 
•  Surgical menopause may result from prophylactic 
oophorectomies (BRCA1 and BRCA2 gene carriers), or 
repeated ovarian surgery for benign disease such as 
ovarian cysts or endometriosis, resulting in damage to 
germ cells.
•  Postponement of fertility may be due to education, 
careers or decisions to delay marriage.
The ability to freeze and store oocytes creates a number of 
opportunities for reproductive medicine. It allows patients 
to postpone maternity for a number of indications, as 
well as circumventing the emotional, religious and ethical 
issues associated with embryo freezing.
Currently approximately 20 - 40 oocytes are necessary to 
achieve one pregnancy, whereas 100 - 150 were necessary 
in the past.3 This indicates that progress has been made 
with regard to the success of cryopreservation of oocytes, 
and each method will have its place in reproductive 
medicine. 
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